CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of
investigational ribonucleic acid interference (RNAi) therapeutics, today
announced that Douglas M. Fambrough, Ph.D., president and chief
executive officer, will participate in an analyst-led fireside chat at
the LEERINK Partners Roundtable Series: Rare Disease and Immuno-Oncology
on Wednesday, September 27, 2017 at 11:00 a.m. ET. The conference will
be held at the Lotte New York Palace in New York City.
A live webcast of the presentation can be accessed on the Investors &
Media section on the Dicerna website at www.dicerna.com.
An archived replay of the webcast will be available on the Company's
website after the conference.
About Dicerna Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, Inc., is a biopharmaceutical company focused on
the discovery and development of innovative, subcutaneously delivered
RNAi-based therapeutics for diseases involving the liver, including rare
diseases, chronic liver diseases, cardiovascular diseases, and viral
infectious diseases. Dicerna is leveraging its proprietary GalXC™ RNAi
technology platform to build a broad pipeline in these core therapeutic
areas, focusing on target genes where connections between target gene
and diseases are well understood and documented. Dicerna intends to
discover, develop and commercialize novel therapeutics either on its own
or in collaboration with pharmaceutical partners. For more information,
please visit www.dicerna.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170920005262/en/
Rx Communications Group
Van Rees, 973-442-1555 ext. 111
Source: Dicerna Pharmaceuticals, Inc.
News Provided by Acquire Media